BioCentury | Apr 28, 2020
Finance

April 27 Quick Takes: Avalyn raises $35M for fibrosis therapies, plus Actym, LifeSprout, HebeCell, Compass, Immunomic

Fibrosis company Avalyn raises $35.5M series B Seattle’s Avalyn Pharma Inc. closed a $35.5 million B round, adding to its $62 million series A in 2017. The round was led by Norwest Venture Partners with...
BioCentury | May 25, 2018
Product R&D

Peptides step up

New screening platforms and synthetic approaches could finally solve some of the longstanding hurdles to turning antimicrobial peptides into therapeutic candidates to combat antibacterial resistance, overcoming their history of limited clinical efficacy, systemic toxicity and...
BioCentury | Oct 6, 2017
Clinical News

BioTime reports additional data for Renevia facial lipoatrophy device

BioTime Inc. (NYSE-M:BTX; Tel Aviv:BTX) reported long-term data from a European pivotal trial of Renevia to treat HIV-associated lipoatrophy, which the company said is a severe form of lipoatrophy characterized by the pathological loss of...
BioCentury | Aug 22, 2017
Distillery Techniques

Imaging

TECHNOLOGY: MRI Iron oxide-based nanoparticles could be used in magnetic resonance angiography (MRA) to diagnose ischemic stroke. The nanoparticles consist of an iron oxide core functionalized with polyethylene glycol (PEG)-phosphine oxide conjugates to enhance solubility...
BioCentury | Aug 16, 2017
Distillery Therapeutics

Neurology

INDICATION: Parkinson’s disease (PD); neurology Mouse studies suggest electromagnetized nanoparticle-mediated in situ reprogramming of somatic cells into dopaminergic neurons could help treat PD. The reprogramming therapy involves lentiviral vectors encoding the dopaminergic neuron transcription factors...
BioCentury | Aug 3, 2017
Emerging Company Profile

Tunable cell therapies

Sigilon Therapeutics Inc. is developing allogeneic cell therapy implants for protein deficiency disorders that thread the needle between protein replacement therapies that require frequent dosing, and gene and cell therapies that are hard to dose-adjust....
BioCentury | Jun 23, 2017
Financial News

Sigilon debuts with $23.5M series A

On June 21, Sigilon Therapeutics Inc. (Cambridge, Mass.) emerged from Flagship Pioneering's VentureLabs incubator with $23.5 million in series A funding from the VC. The newco will use its biocompatible Afibromer technology to develop encapsulated...
BioCentury | Jun 21, 2017
Financial News

Sigilon debuts with $23.5M series A

Sigilon Therapeutics Inc. (Cambridge, Mass.) emerged from Flagship Pioneering's VentureLabs incubator with $23.5 million in series A funding from the VC. The newco will use its biocompatible Afibromer technology to develop encapsulated cell therapies for...
BioCentury | Jun 15, 2017
Tools & Techniques

Clearing chemistry

A new study has discovered an in vivo use of click chemistry that can rapidly clear drugs from circulation in case of emergency. Although it raises the possibility of a universal safety switch, its adoption...
BioCentury | Jan 13, 2017
Company News

InVivo, PixarBio deal

PixarBio proposed to acquire InVivo for $100 million in stock. The combined company would be renamed Reynolds Therapeutics Corp. and focus on pain, spinal cord injury, adaptive technologies, epilepsy and Parkinson's disease. According to PixarBio,...
Items per page:
1 - 10 of 324
BioCentury | Apr 28, 2020
Finance

April 27 Quick Takes: Avalyn raises $35M for fibrosis therapies, plus Actym, LifeSprout, HebeCell, Compass, Immunomic

Fibrosis company Avalyn raises $35.5M series B Seattle’s Avalyn Pharma Inc. closed a $35.5 million B round, adding to its $62 million series A in 2017. The round was led by Norwest Venture Partners with...
BioCentury | May 25, 2018
Product R&D

Peptides step up

New screening platforms and synthetic approaches could finally solve some of the longstanding hurdles to turning antimicrobial peptides into therapeutic candidates to combat antibacterial resistance, overcoming their history of limited clinical efficacy, systemic toxicity and...
BioCentury | Oct 6, 2017
Clinical News

BioTime reports additional data for Renevia facial lipoatrophy device

BioTime Inc. (NYSE-M:BTX; Tel Aviv:BTX) reported long-term data from a European pivotal trial of Renevia to treat HIV-associated lipoatrophy, which the company said is a severe form of lipoatrophy characterized by the pathological loss of...
BioCentury | Aug 22, 2017
Distillery Techniques

Imaging

TECHNOLOGY: MRI Iron oxide-based nanoparticles could be used in magnetic resonance angiography (MRA) to diagnose ischemic stroke. The nanoparticles consist of an iron oxide core functionalized with polyethylene glycol (PEG)-phosphine oxide conjugates to enhance solubility...
BioCentury | Aug 16, 2017
Distillery Therapeutics

Neurology

INDICATION: Parkinson’s disease (PD); neurology Mouse studies suggest electromagnetized nanoparticle-mediated in situ reprogramming of somatic cells into dopaminergic neurons could help treat PD. The reprogramming therapy involves lentiviral vectors encoding the dopaminergic neuron transcription factors...
BioCentury | Aug 3, 2017
Emerging Company Profile

Tunable cell therapies

Sigilon Therapeutics Inc. is developing allogeneic cell therapy implants for protein deficiency disorders that thread the needle between protein replacement therapies that require frequent dosing, and gene and cell therapies that are hard to dose-adjust....
BioCentury | Jun 23, 2017
Financial News

Sigilon debuts with $23.5M series A

On June 21, Sigilon Therapeutics Inc. (Cambridge, Mass.) emerged from Flagship Pioneering's VentureLabs incubator with $23.5 million in series A funding from the VC. The newco will use its biocompatible Afibromer technology to develop encapsulated...
BioCentury | Jun 21, 2017
Financial News

Sigilon debuts with $23.5M series A

Sigilon Therapeutics Inc. (Cambridge, Mass.) emerged from Flagship Pioneering's VentureLabs incubator with $23.5 million in series A funding from the VC. The newco will use its biocompatible Afibromer technology to develop encapsulated cell therapies for...
BioCentury | Jun 15, 2017
Tools & Techniques

Clearing chemistry

A new study has discovered an in vivo use of click chemistry that can rapidly clear drugs from circulation in case of emergency. Although it raises the possibility of a universal safety switch, its adoption...
BioCentury | Jan 13, 2017
Company News

InVivo, PixarBio deal

PixarBio proposed to acquire InVivo for $100 million in stock. The combined company would be renamed Reynolds Therapeutics Corp. and focus on pain, spinal cord injury, adaptive technologies, epilepsy and Parkinson's disease. According to PixarBio,...
Items per page:
1 - 10 of 324